Literature DB >> 23649826

Risk factors for false positive and for false negative test results in screening with fecal occult blood testing.

Inge Stegeman1, Thomas R de Wijkerslooth, Esther M Stoop, Monique van Leerdam, M van Ballegooijen, Roderik A Kraaijenhagen, Paul Fockens, Ernst J Kuipers, Evelien Dekker, Patrick M Bossuyt.   

Abstract

Differences in the risk of a false negative or a false positive fecal immunochemical test (FIT) across subgroups may affect optimal screening strategies. We evaluate whether subgroups are at increased risk of a false positive or a false negative FIT result, whether such variability in risk is related to differences in FIT sensitivity and specificity or to differences in prior CRC risk. Randomly selected, asymptomatic individuals were invited to undergo colonoscopy. Participants were asked to undergo one sample FIT and to complete a risk questionnaire. We identified patient characteristics associated with a false negative and false positive FIT results using logistic regression. We focused on statistically significant differences as well as on variables influencing the false positive or negative risk for which the odds ratio exceeded 1.25. Of the 1,426 screening participants, 1,112 (78%) completed FIT and the questionnaire; 101 (9.1%) had advanced neoplasia. 102 Individuals were FIT positive, 65 (64%) had a false negative FIT result and 66 (65%) a false positive FIT result. Participants at higher age and smokers had a significantly higher risk of a false negative FIT result. Males were at increased risk of a false positive result, so were smokers and regular NSAID users. FIT sensitivity was lower in females. Specificity was lower for males, smokers and regular NSAID users. FIT sensitivity was lower in women. FIT specificity was lower in males, smokers and regular NSAID users. Our results can be used for further evidence based individualization of screening strategies.
Copyright © 2013 UICC.

Entities:  

Keywords:  colorectal cancer; false negative; false positive; fecal immunochemical test; prevention; screening

Mesh:

Year:  2013        PMID: 23649826     DOI: 10.1002/ijc.28242

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

Review 1.  The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands.

Authors:  Frank van Hees; Ann G Zauber; Harriët van Veldhuizen; Marie-Louise A Heijnen; Corine Penning; Harry J de Koning; Marjolein van Ballegooijen; Iris Lansdorp-Vogelaar
Journal:  Gut       Date:  2015-06-10       Impact factor: 23.059

2.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

3.  Nonsteroidal Anti-Inflammatory Drug-Induced Colopathy in a Colorectal Cancer Screening Program.

Authors:  Sanja Borozan; Ljiljana Vuckovic; Brigita Smolovic
Journal:  Med Princ Pract       Date:  2018-10-25       Impact factor: 1.927

4.  Are Hemorrhoids Associated with False-Positive Fecal Immunochemical Test Results?

Authors:  Nam Hee Kim; Jung Ho Park; Dong Il Park; Chong Il Sohn; Kyuyong Choi; Yoon Suk Jung
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

5.  Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer.

Authors:  Julien Peltier; Jean-Pierre Roperch; Stéphane Audebert; Jean-Paul Borg; Luc Camoin
Journal:  Clin Proteomics       Date:  2018-04-09       Impact factor: 3.988

6.  Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain).

Authors:  Isabel Portillo; Eunate Arana-Arri; Isabel Idigoras; Isabel Bilbao; Lorea Martínez-Indart; Luis Bujanda; Iñaki Gutierrez-Ibarluzea
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

7.  Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.

Authors:  Jade Law; Anand Rajan; Harry Trieu; John Azizian; Rani Berry; Simon W Beaven; James H Tabibian
Journal:  Dig Dis Sci       Date:  2021-08-04       Impact factor: 3.487

8.  Advances in Fecal Tests for Colorectal Cancer Screening.

Authors:  Eline H Schreuders; Esmée J Grobbee; Manon C W Spaander; Ernst J Kuipers
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03

9.  Knowledge, attitudes and beliefs regarding colorectal cancer screening among ethnic minority groups in the Netherlands - a qualitative study.

Authors:  Anke J Woudstra; Evelien Dekker; Marie-Louise Essink-Bot; Jeanine Suurmond
Journal:  Health Expect       Date:  2015-11-17       Impact factor: 3.377

10.  Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?

Authors:  Eunate Arana-Arri; Isabel Idigoras; Begoña Uranga; Raquel Pérez; Ana Irurzun; Iñaki Gutiérrez-Ibarluzea; Callum G Fraser; Isabel Portillo
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.